The FDA issued a complete response letter for Corcept’s relacorilant in Cushing’s syndrome, requesting additional efficacy evidence; the company said it will meet with regulators to chart a path forward. Corcept is pivoting to pursue a planned July 2026 PDUFA for relacorilant in platinum‑resistant ovarian cancer. The CRL hit shares and narrows near‑term commercialization options for the selective glucocorticoid receptor antagonist. Regulatory teams should monitor upcoming agency interactions and any clarifying guidance that could affect subsequent oncology filings.